Ligand to Participate in March Investor Conferences

Rhea-AI Summary

Ligand Pharmaceuticals (Nasdaq: LGND) has announced its participation in two major healthcare investor conferences this March 2025. CEO Todd Davis and CFO Tavo Espinoza will represent the company at both events in Miami.

The management team will attend the Leerink Partners Global Healthcare Conference on March 10, engaging in one-on-one meetings with investors. Following this, they will participate in the Barclays 27th Annual Global Healthcare Conference on March 12, where they will join a fireside chat at 12:00 p.m. ET and conduct additional one-on-one meetings.

Investors interested in scheduling individual meetings with Ligand's management should reach out to their Leerink or Barclays representatives to arrange appointments.

News Market Reaction

-8.22%

1 alert

-8.22% News Effect

On the day this news was published, LGND declined 8.22%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences:

• Leerink Partners Global Healthcare Conference (Miami). Management will participate in one-on-one meetings on March 10, 2025.

• Barclays 27^th Annual Global Healthcare Conference (Miami). Management will participate in a fireside chat on March 12, 2025 at 12:00 p.m. ET.
  

Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Leerink or Barclays representative.

About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

Contacts

Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:         
Kellie Walsh
media@ligand.com
(914) 315-6072

FAQ

Which investor conferences will Ligand Pharmaceuticals (LGND) attend in March 2025?

LGND will attend the Leerink Partners Global Healthcare Conference on March 10 and the Barclays 27th Annual Global Healthcare Conference on March 12, 2025, both in Miami.

What type of presentations will LGND make at the March 2025 healthcare conferences?

LGND will conduct one-on-one meetings at the Leerink conference and participate in a fireside chat at 12:00 p.m. ET during the Barclays conference, along with one-on-one meetings.

Who will represent Ligand (LGND) at the March 2025 investor conferences?

CEO Todd Davis and CFO Tavo Espinoza will represent LGND at both conferences.

How can investors schedule meetings with LGND management at these conferences?

Investors should contact their Leerink or Barclays representative to arrange one-on-one meetings with LGND management.